Creative Planning Sells 322 Shares of Insulet Co. (NASDAQ:PODD)

Creative Planning lowered its stake in shares of Insulet Co. (NASDAQ:PODD) by 4.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 7,108 shares of the medical instruments supplier’s stock after selling 322 shares during the quarter. Creative Planning’s holdings in Insulet were worth $1,654,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of PODD. Diversified Trust Co increased its position in Insulet by 90.9% in the second quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after buying an additional 4,348 shares during the last quarter. SG Americas Securities LLC increased its holdings in Insulet by 349.3% in the 1st quarter. SG Americas Securities LLC now owns 29,575 shares of the medical instruments supplier’s stock worth $5,069,000 after acquiring an additional 22,993 shares during the last quarter. Duality Advisers LP raised its stake in Insulet by 89.4% in the 1st quarter. Duality Advisers LP now owns 19,131 shares of the medical instruments supplier’s stock valued at $3,279,000 after acquiring an additional 9,029 shares during the period. Diversify Advisory Services LLC purchased a new stake in Insulet during the first quarter valued at about $1,043,000. Finally, Intech Investment Management LLC boosted its position in Insulet by 113.8% during the first quarter. Intech Investment Management LLC now owns 6,649 shares of the medical instruments supplier’s stock worth $1,140,000 after purchasing an additional 3,539 shares during the period.

Insulet Trading Down 0.4 %

Shares of Insulet stock opened at $232.37 on Wednesday. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71. Insulet Co. has a 1 year low of $128.68 and a 1 year high of $243.98. The firm has a market cap of $16.29 billion, a PE ratio of 42.25, a PEG ratio of 4.36 and a beta of 1.21. The company has a 50 day simple moving average of $224.27 and a two-hundred day simple moving average of $200.35.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). The company had revenue of $488.50 million for the quarter, compared to the consensus estimate of $488.00 million. Insulet had a return on equity of 30.73% and a net margin of 21.11%. The business’s revenue was up 23.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.38 earnings per share. Analysts expect that Insulet Co. will post 3.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on PODD. UBS Group boosted their price target on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Canaccord Genuity Group raised their price target on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. BTIG Research boosted their price objective on Insulet from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Piper Sandler raised their target price on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. Finally, Raymond James upped their price target on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average target price of $242.29.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.